SurGenTec has earned FDA clearance for its proprietary TiLink-L Sacroiliac Joint Fusion System, which can be implanted from a lateral or posterior/oblique approach and uses unique surface technology to optimize bone growth.
This is SurGenTech's inaugural implant in the sacroiliac family of products, according to a June 8 press release.
The TiLink has distinct features from other products on the market, including a design that allows for superior compression across the joint. It is also equipped with SurGenTec's proprietary Nanotex surface technology and boasts a helical self-harvesting channel to capture the patient's own bone and encourage healing, according to the release.
The sacroiliac joint fusion market is projected to witness substantial growth in the coming years as the population ages and the demand for minimally invasive procedures increases.
"We are thrilled to announce the FDA clearance of our first treatment option in our sacroiliac family of products," Travis Greenhalgh, CEO of SurGenTec, said in the release. "With its unique properties and ability to adapt to diverse patient needs, TiLink-L is set to offer physicians the ability to stabilize the sacroiliac joint in a variety of approaches. Whether in an outpatient or hospital setting, we believe this device is poised to make a significant difference in patient care."